It can be postulated that since CXCL10 expression correlates with immune cell infiltration, and HR-negative tumors are more immunogenic than HR-positive tumors, the difference in CXCL10 expression in DCIS and invasive carcinoma may be accentuated in HR-negative tumors. This evidence concerns the gene CXCL10 and ductal breast carcinoma in situ.